{"id":1716,"date":"2023-11-28T09:10:51","date_gmt":"2023-11-28T09:10:51","guid":{"rendered":"https:\/\/gebro.es\/home\/"},"modified":"2025-02-25T09:22:31","modified_gmt":"2025-02-25T09:22:31","slug":"home","status":"publish","type":"page","link":"https:\/\/gebro.es\/ca\/","title":{"rendered":"Home"},"content":{"rendered":"
\n
\n \"\"\n <\/div>\n
\n
\n
\n

Perqu\u00e8 ens importa la vida, millorem la teva salut.<\/h1>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n

Sobre Gebro<\/h2>\n
\n

A Gebro treballem dia rere dia per millorar la salut i la qualitat de les persones unint ci\u00e8ncia, innovaci\u00f3 i talent.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Descobreix m\u00e9s sobre la companyia\n <\/a>\n <\/div>\n
\n
\n

Hist\u00f2ria<\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n
\n \"\"\n <\/div>\n <\/div>\n
\n

Transpar\u00e8ncia i \u00e8tica<\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n
\n \"\"\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n\n
\n
\n
\n

\n Business Development \/Innovaci\u00f3\n <\/h2>\n
\n

Busquem activament sinergies per impulsar la innovaci\u00f3, forjant acords col\u00b7laboratius i de llic\u00e8ncia amb altres empreses en els \u00e0mbits farmac\u00e8utic i biotecnol\u00f2gic.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Saber-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n \n \"\"\n <\/div>\n <\/section>\n\n\n\n
\n
\n
\n

\n Ci\u00e8ncia i recerca\n <\/h2>\n
\n

A Gebro Pharma estem compromesos amb una estrat\u00e8gia d\u2019investigaci\u00f3 din\u00e0mica mitjan\u00e7ant la qual establim sinergies amb prestigiosos socis cient\u00edfics per crear solucions innovadores en les nostres \u00e0rees terap\u00e8utiques.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Explorar m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n \n \"\"\n <\/div>\n <\/section>\n\n\n\n
\n

\u00c0rees terap\u00e8utiques<\/h2>\n
\n
\n

A Gebro Pharma som un referent en les \u00e0rees de dolor, respiratori, malalties autoimmunes i uroginecologia, desenvolupant noves solucions i productes per millorar la qualitat de vida dels pacients.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Llegiu-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n
\n \n \n\n\n\n<\/svg>\n

Malalties autoinmunes<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Dolor<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Respiratori<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Urologia i Ginecologia<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Productes hospitalaris<\/h3>\n <\/a>\n <\/div>\n<\/section>\n\n\n
\n \n \n \"\"\n <\/picture>\n
\n
\n
\n

Productes<\/h2>\n
\n

Descobreix el nostre portfoli de medicaments i productes farmacol\u00f2gics i sanitaris en les diferents \u00e0rees terap\u00e8utiques, les seves presentacions i indicacions.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Veure tots els productes\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n
\n
\n

Altres recursos<\/p>\n <\/div>\n

\n\n \"\"\n\n
\n
\n

\n \"\"\n Gebro Health Talks\n <\/h2>\n
\n

La nostra voluntat \u00e9s compartir coneixement i dialogar amb la comunitat cient\u00edfica. Informa\u2019t m\u00e9s sobre les nostres sessions de formaci\u00f3.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Llegiu-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n

\n \"\"\n Gebro Health Talks\n <\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n \n <\/div>\n\n <\/div>\n
\n\n \"\"\n\n
\n
\n

\n \"\"\n Tu salud\n <\/h2>\n
\n

L\u2019espai per a pacients amb problemes d\u2019asma.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Llegiu-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n

\n \"\"\n Tu salud\n <\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n \n <\/div>\n\n <\/div>\n \n <\/div>\n<\/section>\n\n\n
\n

Patologies<\/h2>\n
\n
\n

Troba informaci\u00f3 detallada sobre les patologies relacionades amb les nostres \u00e0rees terap\u00e8utiques.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Llegiu-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n
\n \n \n\n\n\n<\/svg>\n

Artritis reumatoide<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Asma<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

EPOC<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

S\u00edndrome de la bufeta hiperactiva<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

C\u00e0ncer de bufeta<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Dolor<\/h3>\n <\/a>\n <\/div>\n<\/section>\n\n\n
\n \n \n \"\"\n <\/picture>\n
\n
\n
\n

Talent Gebro<\/h2>\n
\n

Certificada com a empresa Great Place to Work, a Gebro Pharma promovem un entorn saludable on les persones poden desenvolupar tot el seu potencial personal i professional.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n La nostra gent, el nostre ADN\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n

Gebro
Xifres econ\u00f2miques<\/h2>\n
\n
\n
\n 150\n <\/div>\n
\n 94M\u20ac\n <\/div>\n
\n 3M\u20ac\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n
Empleats<\/div>\n
Vendes netes<\/div>\n
Inversi\u00f3 2022<\/div>\n <\/div>\n<\/section>\n\n\n
\n

Not\u00edcies<\/h2>\n
\n
\n

Estigues al dia de les \u00faltimes not\u00edcies, novetats i actualitat de Gebro Pharma.<\/p>\n<\/div>

\n
\n \n
\n \n\n<\/svg>\n<\/div>\n Veure totes les not\u00edcies\n <\/a>\n <\/div>\n
\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n
\n
\n \n \"\"\n <\/a>\n
\n
\n
\n \u00c1reas terap\u00e9uticas<\/a>\n juny 21, 2024<\/span>\n <\/div>\n \n

Gebro Pharma y Adalvo lanzan Dalingo\u00ae (pregabalina de liberaci\u00f3n retardada), un f\u00e1rmaco destinado a los pacientes adultos con dolor neurop\u00e1tico\u00a0<\/h3>\n <\/a>\n <\/div>\n \n

Barcelona, 18 de junio de 2024 \u2013 Laboratorios Gebro Pharma y Adalvo acaban de lanzar al mercado el f\u00e1rmaco Dalingo\u00ae. El producto est\u00e1 indicado en pacientes adultos que padecen dolor neurop\u00e1tico central y perif\u00e9rico. Contiene un \u00fanico principio activo, la pregabalina, y se administra una vez al d\u00eda mediante un comprimido de liberaci\u00f3n prolongada que […]<\/p>\n \n

\n \n\n<\/svg>\n<\/div>\n Llegiu-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n \"\"\n <\/a>\n
\n
\n
\n Press<\/a>\n gener 19, 2024<\/span>\n <\/div>\n \n

Sergi Aulinas (Gebro Pharma): \u201cHay que actuar en el precio de los f\u00e1rmacos regulados esenciales para que sean rentables\u201d<\/h3>\n <\/a>\n <\/div>\n \n

El pasado mes de enero Sergi Aulinas, CEO de Gebro Pharma, realiz\u00f3 una entrevista con el peri\u00f3dico econ\u00f3mico Cinco D\u00edas. En ella cuenta un reciente relanzamiento de un producto de la compa\u00f1\u00eda, hecho posible gracias a un acuerdo coinversiones. Aulinas se\u00f1ala los desaf\u00edos en el acceso a nuevos medicamentos y aboga por una sanidad p\u00fablica […]<\/p>\n \n

\n \n\n<\/svg>\n<\/div>\n Llegiu-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n \"\"\n <\/a>\n
\n
\n
\n Corporate<\/a>\n juny 09, 2023<\/span>\n <\/div>\n \n

BIT Pharma’s Nicaplant\u00ae implants, licensed in Spain by Laboratorios Gebro Pharma, achieve the EMA’s PRIME designation<\/h3>\n <\/a>\n <\/div>\n \n

Laboratorios Gebro Pharma, S.A. and BIT Pharma signed an agreement back in 2022 for the commercialization of Nicaplant\u00ae in Spain, subject to prior regulatory approval. The implants, currently in development, are intended to prevent cerebral vasospasm, a severe complication that occurs in a high percentage of patients who have suffered a subarachnoid hemorrhage. This type […]<\/p>\n \n

\n \n\n<\/svg>\n<\/div>\n Llegiu-ne m\u00e9s\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1716","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nGebro Pharma<\/title>\n\n\n\n\n\n\n\n\n\n\n\t\n